Role of agents for the treatment of diabetes in the management of non-alcoholic fatty liver disease
The goal of K. Cusi et al. was to review evidence about the complex association between NAFLD and T2DM, and highlight the potential for disease co-management with the available medications used for the treatment of diabetes.
Read More
Association of non-alcoholic fatty liver disease and polycystic ovarian syndrome
MM Asfati et al. aimed to evaluate the association between polycystic ovarian syndrome and NAFLD using a large national database.
Read MoreBiomarkers in NASH
Prof. Rautou, France, discusses a critical component of the diagnosis and management of NASH: biomarkers. There are 2 aspects: fibrosis and diagnosis. Diagnosis is a field of investigations. Microvesicles could play a role.
Read MoreRole of agents for the treatment of diabetes in the management of non-alcoholic fatty liver disease
Association of non-alcoholic fatty liver disease and polycystic ovarian syndrome
PPAR’s as critical regulators of metabolism
Prof Roden, Germany explains why PPAR’s are interesting therapeutic targets not only to improve adipose tissue function but also for the liver. The approach can go beyond the improvement of liver function and aim at a more systemic approach with cardiovascular benefits.
Read More
The changing global epidemiology of hepatocellular carcinoma
Hepatocellular carcinoma is the fifth and ninth most commonly diagnosed cancer in men and women, respectively, and the fourth leading cause of cancer mortality worldwide.
Read More
Trimethylamine N-oxide levels are associated with NASH in obese subjects with type 2 diabetes
Trimethylamine N-oxide (TMAO), choline and betaine serum levels have been associated with metabolic diseases including type 2 diabetes (T2D) and non-alcoholic fatty liver disease (NAFLD).
Read More